Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up.
Barda N, Lustig Y, Indenbaum V, Zibly D, Joseph G, Asraf K, Weiss-Ottolenghi Y, Amit S, Kliker L, Abd Elkader B, Ben-Ami E, Canetti M, Koren R, Katz-Likvornik S, Halpern O, Mendelson E, Doolman R, Harats D, Kreiss Y, Mandelboim M, Regev-Yochay G. Barda N, et al. Clin Microbiol Infect. 2023 Jul;29(7):918-923. doi: 10.1016/j.cmi.2023.03.007. Epub 2023 Mar 13. Clin Microbiol Infect. 2023. PMID: 36921715 Free PMC article. Clinical Trial.
Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI).
Katz MA, Harlev EB, Chazan B, Chowers M, Greenberg D, Peretz A, Tshori S, Levy J, Yacobi M, Hirsch A, Amichay D, Weinberger R, Dor AB, Taraday EK, Reznik D, Chayat CB, Sagas D, Zvi HB, Berdinstein R, Rashid G, Avni YS, Mandelboim M, Zuckerman N, Rainy N, Akriv A, Dagan N, Kepten E, Barda N, Balicer RD. Katz MA, et al. Among authors: barda n. Vaccine. 2022 Jan 24;40(3):512-520. doi: 10.1016/j.vaccine.2021.11.092. Epub 2021 Dec 10. Vaccine. 2022. PMID: 34903372 Free PMC article.
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, Giaquinto C, Judd A, Leibovici L, Hernán MA, Lipsitch M, Reis BY, Balicer RD, Dagan N. Cohen-Stavi CJ, et al. Among authors: barda n. N Engl J Med. 2022 Jul 21;387(3):227-236. doi: 10.1056/NEJMoa2205011. Epub 2022 Jun 29. N Engl J Med. 2022. PMID: 35767475 Free PMC article.
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022.
Kliker L, Zuckerman N, Atari N, Barda N, Gilboa M, Nemet I, Abd Elkader B, Fratty IS, Jaber H, Mendelson E, Alroy-Preis S, Kreiss Y, Regev-Yochay G, Mandelboim M. Kliker L, et al. Among authors: barda n. Euro Surveill. 2022 Jul;27(30):2200559. doi: 10.2807/1560-7917.ES.2022.27.30.2200559. Euro Surveill. 2022. PMID: 35904058 Free PMC article.
Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022.
Barda N, Canetti M, Gilboa M, Indenboim V, Asraf K, Weiss-Ottolenghi Y, Amit S, Zibly D, Doolman R, Mendelson E, Harats D, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Barda N, et al. Euro Surveill. 2022 Sep;27(39):2200701. doi: 10.2807/1560-7917.ES.2022.27.39.2200701. Euro Surveill. 2022. PMID: 36177870 Free PMC article.
Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose.
Canetti M, Barda N, Gilboa M, Indenbaum V, Asraf K, Gonen T, Weiss-Ottolenghi Y, Amit S, Doolman R, Mendelson E, Freedman LS, Kreiss Y, Lustig Y, Regev-Yochay G. Canetti M, et al. Among authors: barda n. N Engl J Med. 2022 Dec 1;387(22):2092-2094. doi: 10.1056/NEJMc2211283. Epub 2022 Nov 9. N Engl J Med. 2022. PMID: 36351266 Free PMC article. No abstract available.
59 results